NY-UNIFRAX
27.7.2021 13:02:06 CEST | Business Wire | Press release
Unifrax , a leading manufacturer of high-performance specialty materials, today announced initial results of the first phase of its testing campaign, performed at hte GmbH , leading provider of high throughput technology in catalysis research. These results support the ability of the recently launched FlexCat™ by Unifrax to significantly improve production throughput, increase process runtime and reduce a company’s carbon footprint.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210727005241/en/
FlexCat, a new customizable fiber-based catalyst support material, is designed for use in industrial catalysis, improving the output of hydrogen and specialty gas production, chemical processing, air purification and other chemical manufacturing applications.
Tested by hte GmbH, Unifrax targeted a model reaction of propane dehydrogenation (PDH) as a common industrial process and compared FlexCat to a literature derived and pellet-supported catalyst. Unifrax’s first step into industrial catalysis is a catalyst support material that has been proven to:
Provide enhanced yield and selectivity.
- FlexCat increased output by 20 percent in the initial cycle and retained at least 90 percent conversion activity during the subsequent cycle tested.
- This patented technology provided more tortuosity, maximizing catalyst interaction and producing 50 percent less side products per cycle, including four times less benzene.
Reduce production downtime.
- FlexCat retained its conversion activity throughout the two cycles, offering up to 50 percent reduction in regeneration time and up to 12 percent longer run time.
- FlexCat’s innovative product forms can be up to 10 times lighter than the conventional support being used, reducing loading and unloading time.
Allow for reduced downstream processing and cleaner outputs through plant optimization.
- First lab scale data showed the potential of FlexCat to significantly reduce coking, improve conversion, and increase selectivity; addressing emissions concerns and providing a safer environment for employees and surrounding communities.
“In this latest round of testing, we homed in on specific areas where our industry partners strive to see improvements and derive value – from increased yield, reduced emissions and lower carbon footprints,” said Chad Cannan, senior vice president of research and development, Unifrax. “This next generation of catalysis technology will significantly increase production through existing assets and avoid costly capital expenditures and unnecessary downtime. This data shows that companies can realize greater value through their current production systems and improve their environmental footprint.”
“This collection of data, in partnership with hte GmbH, is a step in the right direction for industrial catalysis,” said John Dandolph, president and CEO, Unifrax. “With FlexCat, we’re working to optimize plant performance and the impact on local communities, focusing on a unique, game-changing solution. In confirming that we can increase output while reducing emissions and overall costs for our industry partners, we are excited to move forward with implementing this new technology to create better and more efficient catalysis that this industry has never seen before.”
With a track record of 75+ years developing and supplying engineered inorganic materials on a large scale to advanced industries worldwide, Unifrax has a deep history of fiber-based technology and manufacturing. As a first step into industrial catalysis for Unifrax, FlexCat offers a revolutionary fiber-based catalytic media that delivers more than the alumina-based catalysis technology used today.
“We look forward to continued collaboration with Unifrax on FlexCat,” said Wolfram Stichert, CEO, hte GmbH. “We’ve already seen promising results from our testing, and we can’t wait to see what’s ahead for this exciting and brand-new technology.”
Customizable for individual partners, processes and specific reactions, FlexCat can be manufactured at scale today. To learn more about FlexCat, visit www.unifrax.com/flexcat .
About Unifrax
Unifrax develops and manufactures high-performance specialty materials used in advanced applications, including high-temperature industrial insulation, electric vehicles, energy storage, filtration and fire protection, among many others. Unifrax products are designed with the ultimate goal of saving energy, reducing pollution and improving safety for people, buildings and equipment by delivering on our commitment to our customers of greener, cleaner, safer solutions for their application challenges. Unifrax has 37 manufacturing facilities operating in 12 countries and employs 2,700+ employees globally. More information is available at www.unifrax.com . For updates, follow us on Twitter , LinkedIn and Facebook .
About hte GmbH
At hte – the high throughput experimentation company, we make R&D in the area of catalysis faster and more productive. We enable cost-effective innovations and reduced time-to-market for new products, thereby allowing our customers in the energy & refining, chemical & petrochemical, and environmental industries to keep ahead of the competition. Our technology and services comprise:
- R&D Solutions: highly efficient contract research programs at hte’s state-of-the-art laboratories in Heidelberg, Germany.
- Technology Solutions: integrated hardware and software solutions, enabling our customers to establish high throughput workflows in their own laboratories.
Our customers benefit from broad technical and scientific expertise, exceptional customer orientation, complete end-to-end solutions, and outstanding data quality. Our close ties with BASF guarantee long-term orientation and stability.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210727005241/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 14:05:00 CEST | Press release
Trained on more than 13,000 patient studies, novel system significantly outperforms existing models by up to 35% A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is d
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 14:00:00 CEST | Press release
New research shows that brands aligned with emotionally heightened moments in live sports can improve ad effectiveness Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The r
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 14:00:00 CEST | Press release
Precemtabart tocentecan (Precem-TcT) is investigated as a potential first-in-class anti-CEACAM5 ADC, for the treatment of metastatic CRC (mCRC) CEACAM5 is overexpressed in the majority of colorectal tumors (~90%), and requires no patient selection Significant unmet need remains for clinically meaningful innovation in colorectal cancer (CRC), the second leading cause of cancer death worldwide Not intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 13:00:00 CEST | Press release
Randomized controlled trial will evaluate both symptom progression and underlying biology Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early
Unpack ’26 sommerrejsetrends: Flere vælger indenlandske rejser, når de tænker mere bevidst over deres rejsevalg21.5.2026 12:35:00 CEST | Pressemeddelelse
Rejsebranchens førende databrevne trendrapport lancerer sin første sommerudgave nogensinde – Unpack ’26 Summer: The Trends in Travel I dag har Hotels.com udgivet Unpack ’26 Summer: The Trends in Travel, den nyeste udgave af virksomhedens førende trendrapport i rejsebranchen, som viser, hvordan rejseadfærd former sommerens rejsevalg. Efterspørgslen på indenlandske rejser præger sommerens ferieplanlægning. Interessen på sociale medier for indenlandske ferier er globalt steget med 77% sammenlignet med sidste år, og 44% af danske rejsende planlægger en indenlandsk rejse denne sommer*. Fra store sportsbegivenheder og koncerter til rejser inspireret af film og tv bygger Unpack ’26 Summer på indsigter fra den årlige hovedrapport Unpack ’26: The Trends in Travel™ for at fremhæve, hvor rejsende tager hen denne sommer. HHver tendens bygger på førstehåndsdata fra Hotels.com® kombineret med indsigter fra rejsende og overvågning af sociale medier. “Denne sommer bliver der stadig rejst – men på nye
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
